1350925-20-0

Basic information

• Product Name: 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one
• Synonyms: 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one
• CAS NO: 1350925-20-0
• Molecular Formula: C7H6ClN3O
• Molecular Weight: 183.59504
• Mol File: 1350925-20-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 433.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.412±0.06 g/cm3(Predicted)
• PKA: 11.53±0.20(Predicted)
• CAS DataBase Reference: 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one(1350925-20-0)
• EPA Substance Registry System: 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one(1350925-20-0)

Safety Data

• Hazardous Substances Data: 1350925-20-0(Hazardous Substances Data)

Usage

General Description

6-Chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one is a chemical compound with a molecular formula C8H6ClN3O. It is a heterocyclic compound containing a pyridine ring and a dihydropyrazinone ring. 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one is known for its potential biological activities, including anti-cancer and anti-inflammatory properties. It has been studied for its potential as a drug candidate for the treatment of various diseases. The synthesis and characterization of 6-chloro-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one are ongoing areas of research in the field of medicinal chemistry and pharmaceuticals.

Upstream product

• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 1350925-19-7 ethyl 2-(2-amino-6-chloropyridin-3-ylamino)acetate 
• 146015-42-1 6-chloro-2-nitropyridine-3-amine 
• 40851-95-4 6-chloropyridine-2,3-diamine 

Downstream Products

• 1350925-21-1 6-chloropyrido[2,3-b]pyrazin-3(4H)-one 
• 1350925-22-2 3,6-dichloropyrido[2,3-b]pyrazine 

Relevant articles and documents

OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION

The present disclosure relates to compounds of Formula (I), its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.